Menu
Recruiting NCT07227259

Health Properties of Pecan Nut Consumption

No phase Interventional Healthy Adults

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: pecan nut.
Who it may be relevant to
Registry conditions: Healthy Adults. Basic parameters: 45 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Assessment of Systematic Health Properties of Pecan Nut Consumption: Gut, Vascular, Metabolic and Cognitive Outcomes

Overview

The main goal of this clinical study is to see if consuming pecan nuts will result in improvements in overall body metabolism such as in blood lipids, markers of inflammation, blood pressure, cognitive performance and changes in bacteria living in the gut in adults 45 to 75 years of age. Participants will take part in two 3-month intervention periods, separated by 4-6 weeks, in random order ( a total of approximately 7 months). During one intervention period, they will include pecan nuts in their diet each day, while during the other intervention period they will avoid pecans in their diet. There will be an initial screening visit to evaluate eligibility and four study visits to the clinic. Participants will be asked to complete some questionnaires about their diet, physical and cognitive health, and provide blood and stool samples, and have their blood pressure measured.

Interventions

  • Other pecan nut
    Dose - 2 ounces of pecan nuts, daily

Primary outcome measures

  • Change in vascular response at 3 months [Time frame: Change from baseline at 3 months]
Secondary outcome measures (12)
  • Change in blood lipids over 3 months [Time frame: Change from baseline at 3 months]
  • Change in markers of inflammation at 3 months [Time frame: change from baseline at 3 months]
  • Change in gut microbiome profile at 3 months [Time frame: Change from baseline at 3 months]
  • Change in blood markers of intestinal permeability at 3 months. [Time frame: Change from baseline at 3 months]
  • Change in blood markers of intestinal permeability at 3 months [Time frame: Change from baseline at 3 months]
  • Change in cognitive function - reaction time at 3 months [Time frame: Change from baseline at 3 months]
  • Change in cognitive function - working memory at 3 months [Time frame: Change from baseline at 3 months]
  • Change in cognitive function - episodic memory at 3 months [Time frame: Change from baseline to 3 months]
  • Change in cognitive function - sustained attention at 3 months [Time frame: Change from baseline at 3 months]
  • Change in quality of life at 3 months [Time frame: Change from baseline at 3 months]
  • Change in sleep quality at 3 months [Time frame: Change from baseline at 3 months]
  • Change in mood over 3 months [Time frame: Change from baseline to 3 months]

Eligibility criteria

Inclusion criteria

BMI of 20-35 kg/m2, ability to understand the intervention instructions, Willingness to follow the dietary intervention, Willingness to provide biological samples (blood and stool) -

Exclusion criteria

Allergy to pecan or other nuts, Cognitive impairment due to dementia of any type and inability to understand or comply with intervention instructions, Use of menopausal hormone replacement therapy, Use of antibiotics or probiotics in the 2 months prior to enrollment, Uncontrolled diabetes with HbA1C of >9.5, Vegetarian/vegan, Any serious medical condition (such as chronic kidney disease of stage 3 or greater, heart failure, active cancer treatment, inflammatory bowel disease, etc.), Consumption of supplements that may interfere with vascular response or gut microbiome, Use of statin drugs for cholesterol lowering.

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Single blind
Primary purpose
Prevention

Study locations

United States · 1 center
  • Ragle Human Nutrition Center, UC Davis campus — Davis

Identifiers

NCT: NCT07227259 · 2340870

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗